Miraculins Announces Improved Detection of Aggressive Prostate Cancer With Combination of PSP94 and Free Over Total PSA Ratio
Discovery Compliments New Approaches to Prostate Cancer Treatment
News & Media
Kane Biotech Receives an Additional Contribution from NRC-IRAP to Develop its DispersinB® Antibiofilm Wound Gel Product
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce that the National Research Council Industrial Research Assistance Program (NRC-IRAP) has inc
Miraculins’ Completed P2V™ Immunoassay Confirms Mass Spectrometry Results
Company concludes research on prostate program and seeks licensing partner
Miraculins Announces Amendment to Private Placement Offering
Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces today an amendment to the terms of its private placement offering (the "Offering") announced on Novemb
LSAM Recognizes Leaders in the Life Science Sector
The Life Science Association of Manitoba (LSAM) awarded its annual Life Science Awards this week. Recognizing the leaders and innovators of the life science community, the awards highlight the great work being done in this growing and dynamic industry.
Genesys Venture Inc. Congratulates DiaMedica Inc., Kane Biotech Inc. and Sanomune Inc.
Genesys Venture Inc. (GVI), a life sciences management services firm, is pleased to congratulate DiaMedica Inc. (TSXV:DMA), Kane Biotech Inc. (TSXV:KNE) and Sanomune Inc. on being selected as winners in Canada’s Top 10 Life Sciences Competition, organized
DispersinB® Topical Wound Gel Passes First Set of Biocompatibility Tests
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that DispersinB® Topical Wound Gel has passed the FDA-recommended Cytotoxicity and Primary Skin
Medicure Launches New Clinical Program
Medicure Inc. (TSX: MPH) is pleased to announce initiation of a clinical program to investigate the efficacy and safety of Avastrem(TM) (pyridoxal 5'- phosphate) for the management of tardive dyskinesia. The Company will provide details of the planned tar